---
title: "Sagimet Maintained at Buy as Strong Cash Runway and Advancing Acne Franchise Support Unchanged $28 Price Target"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286299770.md"
description: "Yun Zhong from Wedbush has maintained a Buy rating on Sagimet Biosciences, Inc. with a price target of $28. The rating is supported by the company's strong cash position, extending its runway through 2028, and positive data from denifanstat's studies. The upcoming Phase 3 acne trial and new product developments are expected to enhance commercial opportunities, indicating potential upside for SGMT shares. Canaccord Genuity also reaffirmed a Buy rating with a higher price target of $49."
datetime: "2026-05-13T17:45:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286299770.md)
  - [en](https://longbridge.com/en/news/286299770.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286299770.md)
---

# Sagimet Maintained at Buy as Strong Cash Runway and Advancing Acne Franchise Support Unchanged $28 Price Target

Yun Zhong, an analyst from Wedbush, maintained the Buy rating on Sagimet Biosciences, Inc. Class A. The associated price target remains the same with $28.00.

Yun Zhong has given his Buy rating due to a combination of factors that underscore Sagimet’s strengthened fundamentals and advancing acne franchise. The company now has ample cash, with recent financing extending its runway through at least 2028, comfortably past the expected Phase 3 readout and potential NDA filing for denifanstat in acne, while the price target remains unchanged at $28.

In addition, positive efficacy and long-term safety data from denifanstat’s China studies reduce perceived clinical risk and support its positioning as a once-daily oral therapy with a clean tolerability profile. The upcoming Phase 3 acne trial, the life-cycle extension via next-generation TVB-3567, and the planned topical FASN inhibitor collectively expand the commercial opportunity, leading Zhong to see meaningful upside in SGMT shares.

In another report released yesterday, Canaccord Genuity also maintained a Buy rating on the stock with a $49.00 price target.

### Related Stocks

- [SGMT.US](https://longbridge.com/en/quote/SGMT.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)

## Related News & Research

- [NeOnc Advances Glioma Programs and Strengthens Financial Position](https://longbridge.com/en/news/286826865.md)
- [Black Diamond Therapeutics Lung Cancer Drug Shows 15.2-Month PFS in Phase 2 Study](https://longbridge.com/en/news/287280796.md)
- [Relay drug shows early promise against rare blood vessel diseases](https://longbridge.com/en/news/287094432.md)
- [BeOne Medicines: Recent FDA Approval Rewrites One-Drug Narrative](https://longbridge.com/en/news/287245995.md)
- [Vertex Says Health Canada Accepts Suzetrigine Application for Review](https://longbridge.com/en/news/287257602.md)